Engineered T Cell Line for Reproducible pMHC Nanoparticle Potency Assays

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack a high-throughput approach to measure the biological and expansive potency of nanoparticles coupled with antigen-major histocompatibility complex (pMHC) molecules in vitro, due to variability with primary cells and poor reproducibility in measuring T-cell receptor (TCR) signaling events.

Innovation Solution

A cell line transduced with a recombinant T cell receptor (TCR) and a TCR-pathway-dependent reporter is used to accurately model primary TCR-MHC peptide interactions, allowing for the measurement of agonistic or antagonistic activity of pMHC complexes, either bound to nanoparticles or alone, by quantifying reporter signals.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If primary T cells are used to measure pMHC potency, then biological relevance is improved, but measurement precision and reproducibility deteriorate due to high inter-experimental variability

Engineering Contradiction:

Improvebiological relevanceVSAvoidreproducibility

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent creates a cell line that copies the essential TCR signaling functionality of primary T cells while eliminating their variability. The cell line expresses a defined TCR specific for the antigen of interest, along with reporter genes that quantify signaling events, providing a reproducible model that captures biological relevance without primary cell variability

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent transforms the measurement system by changing from primary cells (biological variable) to a engineered cell line with controlled parameters. The cell line expresses specific transcription factors (NFAT, NF-kB, AP-1) linked to reporter genes, converting complex T cell activation into quantifiable molecular events that can be measured with high precision

Inventive Principle:

Principle #35Parameter changes

2Reliability

If distal T-cell receptor signaling events are measured, then biological activity is improved, but measurement precision deteriorates due to poor quantitative reproducibility

Engineering Contradiction:

Improvebiological activityVSAvoidquantitative reproducibility

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent replaces the complex mechanical/biological system of whole T cell activation with a simplified molecular reporting system. Transcription factor activity is substituted with fluorescent or luminescent reporter signals that can be quantified precisely, converting difficult-to-measure biological events into robust optical readouts

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces reporter genes as intermediary molecules that mediate between TCR signaling and measurement. The reporters (e.g., NFAT-driven GFP, NF-kB-driven RFP) act as molecular intermediaries that translate intracellular signaling events into quantifiable signals with high measurement precision

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If pMHC density on nanoparticles is varied, then biological activity is improved, but device complexity increases due to difficulty in mimicking the concentration range relationship

Engineering Contradiction:

Improvebiological activityVSAvoidassay complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent creates a universal assay platform that can measure pMHC potency across different nanoparticle formulations and antigen types using the same cell line and reporter system. The methodology provides a standardized approach that works for various pMHC densities and nanoparticle characteristics without requiring method redesign

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides reliable and reproducible measurements of pMHC potency, enabling the development of effective nanomedicines that can reprogram cellular responses and treat autoimmune diseases by accurately assessing antigen-specific T-cell activation.

Implementation Method 1

a cell line transduced with a recombinant T cell receptor (TCR) and a TCR-pathway-dependent reporter is used to accurately model primary TCR-MHC peptide interactions

Methodology Applied

Scientific EffectT cell receptor (TCR) binding:

Implementation Method 2

The JurMA cell line was transduced with a murine TCR specific for the IGRP13-25 peptide bound to murine MHC class II molecules (I-Ad), a TCR pathway-dependent reporter

Methodology Applied

Scientific EffectTranscription factor activation and reporter expression:

Data Source

PatentUS20240201171A1Assay to measure the potency of receptor-ligand interactions in nanomedicines

Publication Date: 2024.06.20 UTI LIMITED PARTNERSHIP

AI summary

Described herein, is an isolated cell comprising a recombinant T cell receptor (TCR) and a TCR-pathway-dependent reporter, wherein the recombinant T cell receptor is specific for a disease-relevant antigen bound to an MHC molecule. Also described are methods of use for the isolated cell as an assay to determine the function or potency of a peptide-major histocompatibility complex (pMHC) coupled to a nanoparticle (pMHC-NP) that can be used as a medicine for treating an autoimmune disease or cancer.